Samsara Sciences
Provides high-quality primary human liver and kidney cells for 3D bioprinting and research applications, enabling advanced tissue models for drug discovery and regenerative medicine.
- CEO / Founder
- Dr. Sharon Presnell
- Team Size
- 2-10
- Stage
- Active
- Latest Round
- Acquired
- Key Investors
- Organovo Holdings Inc.
Technology & Products
Key Products
Primary human hepatocytes; Primary human hepatic stellate cells; Human liver FFPE tissue slides; Snap-frozen tissues; Nucleic acids and profile data
Technological Advantage
Proprietary cell isolation and characterization processes ensure high viability and phenotypic consistency, critical for reproducible 3D bioprinted tissues; leverages parent company Organovo's bioprinting expertise and automation.
Differentiation
Value Proposition
Supplies traceable, well-characterized human liver and kidney cells that reduce variability in 3D bioprinted tissue research, accelerating drug toxicity testing and disease modeling while supporting internal R&D for therapeutic tissues.
How They Differentiate
Specializes exclusively in human liver and kidney cells for 3D bioprinting, with traceable donor origins and comprehensive phenotypic data, unlike generic cell suppliers that lack bioprinting-specific optimization.
Market & Competition
Target Customers
Pharmaceutical companies, academic research institutions, biotech firms
Industry Verticals
Pharmaceutical; Biotechnology; Academic Research; Regenerative Medicine
Competitors
Organovo; Aspect Biosystems; EnvisionTEC
Growth & Milestones
Growth Metrics
Samsara Sciences has $18 million in revenue and 5 employees.
Major Milestones
Launched commercial operations in 2016; Announced multi-year supply agreement with Lonza Bioscience Solutions in 2018; Asset acquisition by LifeNet Health in 2019
Notable Customers
QPS Holdings LLC